Clinical

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

Articles


The real impact may not likely be seen until after July when additional biosimilars referencing Humira are launched.


 Will the Biosimilar Amjevita Lower Costs?

Some PBMs will offer Amgen’s Amjevita biosimilar as a preferred product alongside Humira, but CVS Caremark said Humira will remain preferred and Amjevita will be placed on a non-preferred brand tier.

First Humira Biosimilar is Now Available

A decision is anticipated in early January about which of the now eight Humira biosimilars will be included.

Prime to Cover Biosimilars Alongside Humira

This is the eighth biosimilar to reference the blockbuster rheumatoid arthritis drug Humira that will launch in 2023.

FDA Approves Fresenius Kabi’s Humira Biosimilar

The acceptance of Biogen’s application follows regulator’s acceptance of an application by Fresenius Kabi for another Actemra biosimilar.

FDA Accepts Biogen’s Application for Actemra Biosimilar 

OptumRx will offer Amjevita and two other biosimilars alongside Humira. OptumRx is the first PBM to make public its plans for the seven Humira biosimilars that could be introduced in 2023.

OptumRx to Cover Amgen’s Biosimilar of Humira

Although Xeljanz, Olumiant and Rinvoq are in the same drug class, the risk of serious adverse events from these three products to treat rheumatoid arthritis and other inflammatory conditions may not be similar.

Study: JAK Inhibitors May Have Different Side Effects

Hadlima, a biosimilar of Humira, will be launched next year to treat patients with certain chronic autoimmune diseases.

FDA Approves High Concentration Hadlima

The FDA approved a supplemental BLA for use of Krystexxa with methotrexate for the treatment of uncontrolled gout.

FDA Expands Label for Krystexxa

Riabni is now approved to treat all available Rituxan indications.


Musculoskeletal/Rheumatology